News

Emisphere and Syracuse University have entered into a research agreement to combine Emisphere’s Eligen oral drug delivery technology with a new oral drug delivery system developed in the

Amicus has initiated phase-III trial with its investigational drug, Amigal (migalastat hydrochloride), for the treatment of Fabry disease. The company has reached an agreement with FDA on the

NeurogesX and Astellas Pharma have entered into an exclusive distribution, marketing and license agreement for the commercialization of Qutenza, in the European Economic Area (EEA). The agreement closely

Cordex has signed an agreement with Clinical Trials International (CTI), regarding a license to develop and market Cordex’s drug candidate ATPotent. ATPotent is a novel ATP-based drug candidate

Cell Therapeutics (CTI) has reported pixantrone clinical studies, including follow-up data and subgroup analyses of high risk patients, from the phase-III Extend Pix 301 clinical trial of pixantrone

China Pharma has received official approval from China’ State Food and Drug Administration (SFDA) to enter phase-I and phase-II clinical trials, to test the efficacy of cholesterol-lowering drug,

Merck KGaA has initiated its global phase-III clinical study of the therapeutic cancer vaccine Stimuvax (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. Stimuvax is

Biogen has enrolled its first patient in phase III, randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of PEGylated interferon beta-1a (BIIB017) in patients with

Wyeth has exercised its option under the terms of its collaboration agreement with Trubion, to extend the research period for an additional one-year period through Dec. 22, 2010.